

References

I-138

1. Hendriksz C, Burton B, Fleming T, et al. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. *J Inherit Metab Dis*. 2014;37(6):979-90.
2. Lyseng-Williamson K. Elosulfase Alfa: A Review of Its Use in Patients with Mucopolysaccharidosis Type IVA (Morquio A Syndrome). *BioDrugs*. 2014;(28)465–475.
3. Qi Y, Musson D, Schweighardt B, et al. Pharmacokinetic and Pharmacodynamic Evaluation of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients with Morquio A Syndrome. *Clin Pharmacokinet*. 2014;(53)1137–1147.
4. Cao JD, Wiedemann A, Quinaux T, et al. 30 months follow-up of an early enzyme replacement therapy in a severe Morquio A patient: About one case. *Molecular Genetics and Metabolism Reports*. 2016;42-45.
5. Regier DS, Tanpaiboon P. Role of elosulfase alfa in mucopolysaccharidosis IVA. *The Application of Clinical Genetics*. 2016;9:67–74.
6. Finnigan N, Roberts J, Mercer J, Jones SA. Home infusion with Elosulfase alpha (VimizimR) in a UK Paediatric setting. *Molecular Genetics and Metabolism Reports*. 2017;15–18.
7. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. *Healthcare*. 2016. Accessed November 7, 2017.
8. ASHP Guidelines on Home Infusion Pharmacy Services, 2013. Accessed September 2, 2017.
9. MCG™ Care Guidelines, 21st edition, 2017, Home Infusion Therapy, CMT: CMT-0009(SR).
10. MICROMEDEX®SOLUTIONS Compendia. 2017. Elosulfase Alfa.
11. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Elosulfase alfa.